Physician profile
Fernando Boccalandro
NPI 1467441428
$4,215.20
in general payments reported to CMS, 2019-2025
33 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $483 · 2021: $438 · 2022: $602 · 2023: $548 · 2024: $578 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,296.94 | 2019-2025 | Aveir, Cardiomems, Ultreon |
| Astrazeneca Pharmaceuticals LP | $330.17 | 2019-2025 | Farxiga, Lokelma |
| Medtronic, INC. | $312.72 | 2022-2025 | Corevalve Evolut R, Abre |
| Amgen INC. | $300.96 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $235.93 | 2019-2025 | |
| Janssen Research & Development, LLC | $222.00 | 2021 | |
| Boston Scientific Corporation | $191.53 | 2022-2024 | Watchman Access System, Ekosonic, Eluvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.21 | 2025 | Jardiance |
| Inari Medical, INC. | $164.62 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abiomed | $133.74 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $129.74 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $88.12 | 2020-2021 | |
| United Therapeutics Corporation | $85.11 | 2019-2020 | |
| Philips North America LLC | $82.55 | 2019-2021 | |
| Siemens Medical Solutions USA, INC. | $68.07 | 2019-2023 | Artis Icono Floor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $66.61 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $65.74 | 2019 | |
| Ge Healthcare | $38.75 | 2023 | |
| Amarin Pharma, INC. | $36.08 | 2019 | |
| Dexcom, INC. | $31.53 | 2021-2022 | |
| Teleflex LLC | $24.33 | 2025 | Orsiro Mission |
| Lantheus Medical Imaging, INC. | $23.53 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $20.28 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $17.72 | 2020 | |
| Vivus LLC | $17.36 | 2021 | |
| Chiesi USA, INC. | $14.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.47 | 2019 | |
| Medtronic Vascular, INC. | $13.59 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Boccalandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.